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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).We read with interest the recent study by Mahmoud MA et
al. documenting poor knowledge of adverse drug reaction
(ADR) reporting processes among community pharmacists
in Riyadh, ‘‘Community pharmacists’ knowledge, behaviors
and experiences about adverse drug reaction reporting in
Saudi Arabia’’ (Mahmoud et al., 2014). Unfortunately, these
ﬁndings are consistent with our research in Qatar where we
conducted a survey to describe pharmacist knowledge,
experience, attitudes, and perceived barriers to ADR report-
ing (Wilbur, 2013). Given their leading role in the region
with such drug safety infrastructure as the Saudi Federal
Drug Association, it is discouraging that the majority
(87%) of community pharmacists of the studied sample in
Saudi Arabia were familiar with the country’s ADR
reporting system. In Qatar, no community or ambulatory
care pharmacist we surveyed had ever made a report and
we found lack of clarity regarding the ultimate fate of
submitted reports by these and other pharmacists
(inpatient-based) (Wilbur, 2012). Although recently admitted
as an associate member to the WHO Programme for
International Drug Monitoring, Qatar, unlike Saudi
Arabia, does not beneﬁt from a national pharmacovigilance
center or abilities to submit suspected ADR reports online.
Discrepancies did exist in some barriers cited by our respec-
tive study populations. We found inability to recognize a
suspected ADR was a discouraging factor for 40% of
Qatar pharmacists, whereas 17% of the Saudi Arabia com-
munity pharmacists felt most ADRs encountered in their
practice were not serious enough to merit reporting. While
just 6% in our colleagues’ research indicated workload as
a barrier to reporting, such time restrictions were given by
21% in Qatar. Having said this, there appears a common
sign of reporting motivation as 84% of these Qatarpharmacists declared it a professional responsibility to sub-
mit suspected ADR documentation and similarly, only 20%
in Saudi Arabia felt it was not their duty.
What can be done to promote pharmacovigilance in the
Gulf Coast Cooperation (GCC) region? Low rates of phar-
macist suspected ADR reporting have also been encountered
elsewhere in Saudi Arabia and in the United Arab Emirates
(Dameh, 2015; Khan, 2013). As put forth by Mahmoud MA
et al., there is a need for more pharmacovigilance training
programs for pharmacists, and the potential to harness
‘informal’ educational opportunities through the inﬂuence
of pharmacy students participating in community intern-
ships. Preferences of Qatar pharmacists were to have a
single accessible reporting form with web-based submission
capabilities, but by the Saudi Arabian experience reported
in this paper, such an instrument would require promotion
and instructions to ensure uptake by users. Given the
proliferation of mobile technologies in the region, a smart
phone application may be the most practical platform. We
also propose greater collaboration within existing regional
infrastructures, such as the Gulf Central Committee for
Drug Registration (Wilbur, 2013). While pharmacists,
especially in community practices, are in unique position
to gather data as they monitor the safety of therapy among
patients, engagement of all parties in the drug use process
(prescribers, nurses, patients) is necessary for widespread
pharmacovigilance success.References
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